Pharmacological aspects of cannabinoids
https://doi.org/10.21886/2712-8156-2023-4-3-27-35
Abstract
This review presents recently available information on the properties of endogenous and exogenous cannabinoids, their possible mechanisms of action and effects. The article reflects foreign experience in the use of cannabinoid preparations for the recommended indications, as well as possible promising effects for the expansion of their clinical use.
About the Authors
A. V. Safronenko
Rostov State Medical University
Russian Federation
Russian Federation
Safronenko Andrey V. - Dr. Sci. (Med.), Docent, Head of Department of Pharmacology and Clinical Pharmacology.
Rostov-on-Don
N. Yu. Saenko
Rostov State Medical University
Russian Federation
Russian Federation
Saenko Natalya Yu. -- Cand. Sci. (Med.), Associate Professor of the Department of Pharmacology and Clinical Pharmacology.
Rostov-on-Don
V. P. Zemliakova
Rostov State Medical University
Russian Federation
Russian Federation
Zemliakova Vladislava P. - 3rd year student, Faculty of General Medicine.
Rostov-on-Don
S. K. Kvaratskheliia
Rostov State Medical University
Russian Federation
Russian Federation
Kvaratskheliia Salome K. - 3rd year student, Faculty of General Medicine.
Rostov-on-Don
M. V. Dolnikova
Rostov State Medical University
Russian Federation
Russian Federation
Dolnikova Mariia V. - 3rd year student, Faculty of General Medicine.
Rostov-on-Don
References
1. Pantoja-Ruiz C, Restrepo-Jimenez P, Castañeda-Cardona C, Ferreirós A, Rosselli D. Cannabis and pain: a scoping review. Braz J Anesthesiol. 2022;72(1):142-151. DOI:10.1016/j.bjane.2021.06.018
2. Crocq MA. History of cannabis and the endocannabinoid system. Dialogues Clin Neurosci. 2020;22(3):223-228. DOI:10.31887/DCNS.2020.22.3/mcrocq
3. Adams R, Hunt M, Clark JH. Structure of Cannabidiol, a Product Isolated from the Marihuana Extract of Minnesota Wild Hemp. J. Am. Chem. Soc. 1940;62(1):196-200. DOI: 10.1021/ja01858a058
4. Gaoni Y, Mechoulam R. Isolation, Structure, and Partial Synthesis of an Active Constituent of Hashish. J. Am. Chem. Soc. 1964;86(8):1646-1647. DOI: 10.1021/ja01062a046
5. Devane WA, Dysarz FA 3rd, Johnson MR, Melvin LS, Howlett AC. Determination and characterization of a cannabinoid receptor in rat brain. Mol Pharmacol. 1988;34(5):605-613. PMID: 2848184
6. Devane WA, Hanus L, Breuer A, Pertwee RG, Stevenson LA, Griffin G, et al. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science. 1992;258(5090):1946-1949. DOI:10.1126/science.1470919
7. Munro S, Thomas KL, Abu-Shaar M. Molecular characterization of a peripheral receptor for cannabinoids. Nature. 1993;365(6441):61-65. DOI:10.1038/365061a0
8. Sugiura T, Kondo S, Sukagawa A, Nakane S, Shinoda A, Itoh K, et al. 2-Arachidonoylglycerol: a possible endogenous cannabinoid receptor ligand in brain. Biochem Biophys Res Commun. 1995;215(1):89-97. DOI:10.1006/bbrc.1995.2437
9. Ahmad A. Endocannabinoid system: An untold story in hypertensive nephropathy. Electron J Gen Med. 2023;20(3):em481. DOI:10.29333/ejgm/13055
10. Amin MR, Ali DW. Pharmacology of Medical Cannabis. Adv Exp Med Biol. 2019;1162:151-165. DOI:10.1007/978-3-030-21737-2_8
11. Morris G, Walder K, Kloiber S, Amminger P, Berk M, Bortolasci CC, et al. The endocannabinoidome in neuropsychiatry: Opportunities and potential risks. Pharmacol Res. 2021;170:105729. DOI:10.1016/j.phrs.2021.105729
12. Lu HC, Mackie K. Review of the Endocannabinoid System. Biol Psychiatry Cogn Neurosci Neuroimaging. 2021;6(6):607-615. DOI:10.1016/j.bpsc.2020.07.016
13. Palmisano M, Gargano A, Olabiyi BF, Lutz B, Bilkei-Gorzo A. Hippocampal Deletion of CB1 Receptor Impairs Social Memory and Leads to Age-Related Changes in the Hippocampus of Adult Mice. Int J Mol Sci. 2022;24(1):26. DOI:10.3390/ijms24010026
14. Meyer JS, Farrar AM. Marijuana and the Cannabinoids. In: Biezonski D, Yates JR, editors. Psychopharmacology. Drugs, the brain, behavior. 4th ed. Sunderland, Massachusetts, USA: Oxford University Press; 2023. p. 445-482.
15. Scarante FF, Vila-Verde C, Detoni VL, Ferreira-Junior NC, Guimarães FS, Campos AC. Cannabinoid Modulation of the Stressed Hippocampus. Front Mol Neurosci. 2017;10:411. DOI:10.3389/fnmol.2017.00411
16. Moore CF, Weerts EM. Cannabinoid tetrad effects of oral Δ9-tetrahydrocannabinol (THC) and cannabidiol (CBD) in male and female rats: sex, dose-effects and time course evaluations. Psychopharmacology (Berl). 2022;239(5):1397-1408. DOI:10.1007/s00213-021-05995-5
17. Lucas CJ, Galettis P, Schneider J. The pharmacokinetics and the pharmacodynamics of cannabinoids. Br J Clin Pharmacol. 2018;84(11):2477-2482. DOI:10.1111/bcp.13710
18. Fraguas-Sánchez AI, Torres-Suárez AI. Medical Use of Cannabinoids. Drugs. 2018;78(16):1665-1703. DOI:10.1007/s40265-018-0996-1
19. Prieto González JM, Vila Silván C. Safety and tolerability of nabiximols oromucosal spray: a review of more than 15 years" accumulated evidence from clinical trials. Expert Rev Neurother. 2021;21(7):755-778. DOI:10.1080/14737175.2021.1935879
20. Abu-Sawwa R, Stehling C. Epidiolex (Cannabidiol) Primer: Frequently Asked Questions for Patients and Caregivers. J Pediatr Pharmacol Ther. 2020;25(1):75-77. DOI:10.5863/1551-6776-25.1.75
21. Georgieva D, Langley J, Hartkopf K, Hawk L, Margolis A, Struck A, et al. Real-world, long-term evaluation of the tolerability and therapy retention of Epidiolex® (cannabidiol) in patients with refractory epilepsy. Epilepsy Behav. 2023;141:109159. DOI:10.1016/j.yebeh.2023.109159
22. Tagen M, Klumpers LE. Review of delta-8-tetrahydrocannabinol (Δ8 -THC): Comparative pharmacology with Δ9 -THC. Br J Pharmacol. 2022;179(15):3915-3933. DOI:10.1111/bph.15865
23. Legare CA, Raup-Konsavage WM, Vrana KE. Therapeutic Potential of Cannabis, Cannabidiol, and Cannabinoid-Based Pharmaceuticals. Pharmacology. 2022;107(3-4):131-149. DOI:10.1159/000521683
24. Badowski ME. A review of oral cannabinoids and medical marijuana for the treatment of chemotherapy-induced nausea and vomiting: a focus on pharmacokinetic variability and pharmacodynamics. Cancer Chemother Pharmacol. 2017;80(3):441-449. DOI:10.1007/s00280-017-3387-5
25. Cohen K, Weizman A, Weinstein A. Positive and Negative Effects of Cannabis and Cannabinoids on Health. Clin Pharmacol Ther. 2019;105(5):1139-1147. DOI:10.1002/cpt.1381
26. Rock EM, Parker LA. Constituents of Cannabis Sativa. Adv Exp Med Biol. 2021;1264:1-13. DOI:10.1007/978-3-030-57369-0_1
27. Mlost J, Bryk M, Starowicz K. Cannabidiol for Pain Treatment: Focus on Pharmacology and Mechanism of Action. Int J Mol Sci. 2020;21(22):8870. DOI:10.3390/ijms21228870
28. Yu W, Jin G, Zhang J, Wei W. Selective Activation of Cannabinoid Receptor 2 Attenuates Myocardial Infarction via Suppressing NLRP3 Inflammasome. Inflammation. 2019;42(3):904-914. DOI:10.1007/s10753-018-0945-x
29. Wu HM, Kim TH, Kim A, Koo JH, Joo MS, Kim SG. Liver X Receptor α-Induced Cannabinoid Receptor 2 Inhibits Ubiquitin-Specific Peptidase 4 Through miR-27b, Protecting Hepatocytes From TGF-β. Hepatol Commun. 2019;3(10):1373-1387. DOI:10.1002/hep4.1415
30. Tartakover Matalon S, Ringel Y, Konikoff F, Drucker L, Pery S, Naftali T. Cannabinoid receptor 2 agonist promotes parameters implicated in mucosal healing in patients with inflammatory bowel disease. United European Gastroenterol J. 2020;8(3):271-283. DOI:10.1177/2050640619889773
31. Zhu M, Yu B, Bai J, Wang X, Guo X, Liu Y, et al. Cannabinoid Receptor 2 Agonist Prevents Local and Systemic Inflammatory Bone Destruction in Rheumatoid Arthritis. J Bone Miner Res. 2019;34(4):739-751. DOI:10.1002/jbmr.3637
32. Cabañero D, Ramírez-López A, Drews E, Schmöle A, Otte DM, Wawrzczak-Bargiela A, et al. Protective role of neuronal and lymphoid cannabinoid CB2 receptors in neuropathic pain. Elife. 2020;9:e55582. DOI:10.7554/eLife.55582
33. Krzyżewska A, Baranowska-Kuczko M, Mińczuk K, Kozłowska H. Cannabinoids—A New Perspective in Adjuvant Therapy for Pulmonary Hypertension. Int. J. Mol. Sci. 2021;22(18):10048. DOI:10.3390/ijms221810048
Supplementary files
Review
For citations:
Safronenko A.V., Saenko N.Yu., Zemliakova V.P., Kvaratskheliia S.K., Dolnikova M.V. Pharmacological aspects of cannabinoids. South Russian Journal of Therapeutic Practice. 2023;4(3):27-35. (In Russ.) https://doi.org/10.21886/2712-8156-2023-4-3-27-35
Views:
15770
Email this article 